Last reviewed · How we verify
DOR/3TC/TDF
DOR/3TC/TDF is a Antiretroviral combination therapy (NNRTI + NRTI + NtRTI) Small molecule drug developed by Prism Health North Texas. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced adults. Also known as: Delstrigo, MK-1439A.
DOR/3TC/TDF is a fixed-dose combination of three antiretroviral agents that work together to inhibit HIV replication through different mechanisms: reverse transcriptase inhibition and nucleotide reverse transcriptase inhibition.
DOR/3TC/TDF is a fixed-dose combination of three antiretroviral agents that work together to inhibit HIV replication through different mechanisms: reverse transcriptase inhibition and nucleotide reverse transcriptase inhibition. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.
At a glance
| Generic name | DOR/3TC/TDF |
|---|---|
| Also known as | Delstrigo, MK-1439A |
| Sponsor | Prism Health North Texas |
| Drug class | Antiretroviral combination therapy (NNRTI + NRTI + NtRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Doravirine (DOR) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase. Lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) that are incorporated into the growing viral DNA chain, causing chain termination. Together, these three agents suppress HIV replication by targeting reverse transcriptase through complementary mechanisms.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
- Rash
- Renal impairment (TDF-related)
- Bone density loss (TDF-related)
Key clinical trials
- Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066) (PHASE2)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity (PHASE3)
- DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road) (PHASE2)
- Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF? (PHASE4)
- A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy (PHASE3)
- Adipose Tissue After Switch to Doravirine (NA)
- The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DOR/3TC/TDF CI brief — competitive landscape report
- DOR/3TC/TDF updates RSS · CI watch RSS
- Prism Health North Texas portfolio CI
Frequently asked questions about DOR/3TC/TDF
What is DOR/3TC/TDF?
How does DOR/3TC/TDF work?
What is DOR/3TC/TDF used for?
Who makes DOR/3TC/TDF?
Is DOR/3TC/TDF also known as anything else?
What drug class is DOR/3TC/TDF in?
What development phase is DOR/3TC/TDF in?
What are the side effects of DOR/3TC/TDF?
What does DOR/3TC/TDF target?
Related
- Drug class: All Antiretroviral combination therapy (NNRTI + NRTI + NtRTI) drugs
- Target: All drugs targeting HIV reverse transcriptase
- Manufacturer: Prism Health North Texas — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced adults
- Also known as: Delstrigo, MK-1439A
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing